SEC Form 4 · accession 0001209191-19-012651
IRONWOOD PHARMACEUTICALS INC · IRWD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas A McCourt
Officer — Chief Commercial Officer
Period of report
Feb 20, 2019
Accepted (ET)
Feb 22, 2019 · 4:53 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001446847
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common StockF1,F2 | Feb 20, 2019 | S | 1,212 | $14.31 | D | 86,938 | D | |
| Class A Common StockF3,F2 | Feb 20, 2019 | S | 1,957 | $14.31 | D | 84,981 | D | |
| Class A Common StockF4,F2 | Feb 20, 2019 | S | 1,631 | $14.31 | D | 83,350 | D | |
| Class A Common StockF1,F5 | Feb 21, 2019 | S | 10 | $14.32 | D | 83,340 | D | |
| Class A Common StockF3,F5 | Feb 21, 2019 | S | 17 | $14.32 | D | 83,323 | D | |
| Class A Common StockF4,F5 | Feb 21, 2019 | S | 14 | $14.32 | D | 83,309 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 16, 2015.
- F2The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.12 to $14.59, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- F3This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 27, 2017.
- F4This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 21, 2018.
- F5The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.24 to $14.38, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.